Rituximab and Plasmapheresis for Post-transplant Recurrence of FSGS / 대한신장학회지
Korean Journal of Nephrology
; : 292-295, 2010.
Article
Dans Ko
| WPRIM
| ID: wpr-87916
Responsable en Bibliothèque :
WPRO
ABSTRACT
Focal segmental glomerular sclerosis (FSGS) is known to recur in 20-40% of the renal allografts with graft loss in about half of these cases. We report a successful treatment of a recurrent FSGS after kidney transplantation with rituximab and plasmapheresis. An 16-year-old patient whose primary kidney disease was FSGS developed recurrence of proteinuria after living donor kidney transplantation despite preemptive plasmapheresis and one dose of rituximab (375 mg/m2). After kidney transplantation, nephrotic range proteinuria was detected. Kidney biopsy was done and showed recurrent FSGS. She undergone 11 times of plasmapheresis in the first 4 week post transplantation. In addition, she received additional one dose of rituximab (375 mg/m2) on day 14. Proteinuria was decreased below nephrotic range at 37 day. Ten months later, proteinuria was at 30 mg/day with excellent graft function. No significant adverse events related to rituximab or plasmapheresis were observed. Rituximab with plasmapheresis may be another option for recurrent FSGS after kidney transplantation.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Protéinurie
/
Récidive
/
Sclérose
/
Transplantation homologue
/
Biopsie
/
Glomérulonéphrite segmentaire et focale
/
Transplantation rénale
/
Plasmaphérèse
/
Donneur vivant
/
Transplants
Limites du sujet:
Adolescent
/
Humans
langue:
Ko
Texte intégral:
Korean Journal of Nephrology
Année:
2010
Type:
Article